Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Chemoembolization, Therapeutic"" wg kryterium: Temat


Tytuł:
Child-Pugh grade deterioration stratified by the etiology after transcatheter arterial chemoembolization as initial treatment for hepatocellular carcinoma.
Autorzy:
Yoshitomi K; Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Hayashi T; Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan. .; Department of Hepatology, Sendai Kousei Hospital, 4-15 Hirosemachi, Aoba-Ku, Sendai, 980-0873, Japan. .
Oe S; Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Shibata M; Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Honma Y; Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Harada M; Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Kooka Y; Department of Hepatology, Sendai Kousei Hospital, 4-15 Hirosemachi, Aoba-Ku, Sendai, 980-0873, Japan.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Feb 14; Vol. 14 (1), pp. 3707. Date of Electronic Publication: 2024 Feb 14.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/pathology
Liver Neoplasms*/pathology
Chemoembolization, Therapeutic*/adverse effects
Chemoembolization, Therapeutic*/methods
Hepatitis C*/complications
Hepatitis C*/therapy
Humans ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Discussing the safety and effectiveness of transcatheter arterial embolization combined with intravenous chemotherapy in treating locally advanced breast cancer.
Autorzy:
Zhang J; Jianyang People's Hospital, Jianyang City, 641400, Sichuan Province, China.
Zhang J; The First Affiliated Hospital of Chengdu Medical College, Chengdu City, Sichuan Province, China.
Niu X; Affiliated Hospital of Chengdu University, Chengdu City, Sichuan Province, China.
Zhou Y; Jianyang People's Hospital, Jianyang City, 641400, Sichuan Province, China.
Guo Y; Jianyang People's Hospital, Jianyang City, 641400, Sichuan Province, China.
Wang Y; Jianyang People's Hospital, Jianyang City, 641400, Sichuan Province, China.
Shou F; Jianyang People's Hospital, Jianyang City, 641400, Sichuan Province, China. shou_.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Mar 12; Vol. 14 (1), pp. 6003. Date of Electronic Publication: 2024 Mar 12.
Typ publikacji:
Randomized Controlled Trial; Journal Article
MeSH Terms:
Breast Neoplasms*/drug therapy
Carcinoma, Hepatocellular*/pathology
Liver Neoplasms*/pathology
Chemoembolization, Therapeutic*
Humans ; Female ; Treatment Outcome ; Doxorubicin
Czasopismo naukowe
Tytuł:
Construction of a prognostic model for hepatocellular carcinoma patients receiving transarterial chemoembolization treatment based on the Tumor Burden Score.
Autorzy:
Lin J; Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Li J; Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.; Liver Cancer Institute, Zhongshan Hospital of Fudan University, Shanghai, China.
Kong Y; Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Yang J; Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Zhang Y; Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Zhu G; Department of Interventional Radiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Yu Z; Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Xia J; Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. .; Liver Cancer Institute, Zhongshan Hospital of Fudan University, Shanghai, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2024 Mar 06; Vol. 24 (1), pp. 306. Date of Electronic Publication: 2024 Mar 06.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/therapy
Liver Neoplasms*/therapy
Chemoembolization, Therapeutic*
Humans ; Prognosis ; Retrospective Studies ; Tumor Burden
Czasopismo naukowe
Tytuł:
Liver transplantation for advanced hepatocellular carcinoma after downstaging with consequential lenvatinib, transcatheter arterial chemoembolization and camrelizumab.
Autorzy:
Peng W; Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China.; Chinese Evidence-based Medicine Center, West China Hospital, Sichuan University, Chengdu, China.
Wu Y; Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China.
Zhang X; Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China.
Li C; Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China.
Shen J; Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China.
Chen W; Department of Radiology, West China Hospital, Sichuan University, Chengdu, China.
Li Q; Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Ma J; Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Yang Y; Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Lu W; Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China.
Liu Z; Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Sun X; Chinese Evidence-based Medicine Center, West China Hospital, Sichuan University, Chengdu, China.
Yang J; Transplant Center & Laboratory of Liver Transplantation, West China Hospital, Sichuan University, Chengdu, China.
Zhou Y; Transplant Center & Laboratory of Liver Transplantation, West China Hospital, Sichuan University, Chengdu, China.
Wen T; Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China.
Pokaż więcej
Źródło:
The British journal of surgery [Br J Surg] 2024 Mar 02; Vol. 111 (3).
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/therapy
Liver Transplantation*
Chemoembolization, Therapeutic*
Liver Neoplasms*/therapy
Phenylurea Compounds*
Quinolines*
Antibodies, Monoclonal, Humanized*
Humans
Czasopismo naukowe
Tytuł:
Development of a Nomogram Using the Inflammatory Risk Score for Prognostication in Moderate and Advanced Hepatocellular Carcinoma Associated with Hepatitis B Virus.
Autorzy:
Chen H; Hunan Provincial Hospital of Integrated Traditional Chinese and Western, Cancer Research Institute of Hunan Academy of Traditional Chinese Medicine, Hunan Academy of Chinese Medicine, Hunan, China.; Hunan University of Chinese Medicine, Hunan, China.
Yang R; Hunan Provincial Hospital of Integrated Traditional Chinese and Western, Cancer Research Institute of Hunan Academy of Traditional Chinese Medicine, Hunan Academy of Chinese Medicine, Hunan, China.; Hunan University of Chinese Medicine, Hunan, China.
Yu X; Hunan Provincial Hospital of Integrated Traditional Chinese and Western, Cancer Research Institute of Hunan Academy of Traditional Chinese Medicine, Hunan Academy of Chinese Medicine, Hunan, China.
Li K; Hunan Provincial Hospital of Integrated Traditional Chinese and Western, Cancer Research Institute of Hunan Academy of Traditional Chinese Medicine, Hunan Academy of Chinese Medicine, Hunan, China.
Xue P; Hunan University of Chinese Medicine, Hunan, China.
Peng W; Hunan Provincial Hospital of Integrated Traditional Chinese and Western, Cancer Research Institute of Hunan Academy of Traditional Chinese Medicine, Hunan Academy of Chinese Medicine, Hunan, China.
Zeng P; Hunan Provincial Hospital of Integrated Traditional Chinese and Western, Cancer Research Institute of Hunan Academy of Traditional Chinese Medicine, Hunan Academy of Chinese Medicine, Hunan, China.
Pokaż więcej
Źródło:
Balkan medical journal [Balkan Med J] 2024 Mar 01; Vol. 41 (2), pp. 130-138.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/complications
Carcinoma, Hepatocellular*/diagnosis
Liver Neoplasms*/complications
Liver Neoplasms*/diagnosis
Chemoembolization, Therapeutic*
Humans ; Hepatitis B virus ; Nomograms ; Retrospective Studies ; Risk Factors ; Inflammation
Czasopismo naukowe
Tytuł:
Transarterial Chemoembolization with Epirubicin-Loaded Microspheres for Hepatocellular Carcinoma: A Prospective, Single-Arm, Multicenter, Phase 2 Study (STOPPER Trial).
Autorzy:
Zhu HD; Center of Interventional Radiology and Vascular Surgery, Department of Radiology, Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology (Southeast University), Basic Medicine Research and Innovation Center of Ministry of Education, Zhongda Hospital, Medical School, Southeast University, 87 Dingjiaqiao Road, Nanjing, 210009, China.
Li X; Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Sun JH; Division of Hepatobiliary and Pancreatic Surgery, Hepatobiliary and Pancreatic Interventional Treatment Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Zhu X; Interventional Therapy Department, Peking University Cancer Hospital and Institute, Beijing, China.
Liu ZY; Department of Radiology, Shengjing Hospital of China Medical University, Shenyang, China.
Li HL; Department of Minimal-Invasive Intervention, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
Lu J; Center of Interventional Radiology and Vascular Surgery, Department of Radiology, Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology (Southeast University), Basic Medicine Research and Innovation Center of Ministry of Education, Zhongda Hospital, Medical School, Southeast University, 87 Dingjiaqiao Road, Nanjing, 210009, China.
Yan ZP; Department of Interventional Radiology, Zhongshan Hospital, Fudan University Shanghai Institution of Medical Imaging, Fudan University, Shanghai, China.
Shao GL; Department of Intervention, The Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer, Chinese Academy of Sciences, Hangzhou, China.
He XF; Division of Vascular and Interventional Radiology, Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Chao M; Department of Radiology, Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou, China.
Lu LG; Zhuhai Interventional Medical Center, Zhuhai Precision Medical Center, Zhuhai People's Hospital, Zhuhai Hospital Affiliated with Jinan University, Jinan University, Zhuhai, China.
Zhong BY; Department of Interventional Radiology, The First Affiliated Hospital of Soochow University, Soochow University, Suzhou, China.
Li R; Center of Interventional Radiology and Vascular Surgery, Department of Radiology, Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology (Southeast University), Basic Medicine Research and Innovation Center of Ministry of Education, Zhongda Hospital, Medical School, Southeast University, 87 Dingjiaqiao Road, Nanjing, 210009, China.
Zhang Q; Center of Interventional Radiology and Vascular Surgery, Department of Radiology, Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology (Southeast University), Basic Medicine Research and Innovation Center of Ministry of Education, Zhongda Hospital, Medical School, Southeast University, 87 Dingjiaqiao Road, Nanjing, 210009, China.
Teng GJ; Center of Interventional Radiology and Vascular Surgery, Department of Radiology, Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology (Southeast University), Basic Medicine Research and Innovation Center of Ministry of Education, Zhongda Hospital, Medical School, Southeast University, 87 Dingjiaqiao Road, Nanjing, 210009, China. .
Pokaż więcej
Źródło:
Cardiovascular and interventional radiology [Cardiovasc Intervent Radiol] 2024 Mar; Vol. 47 (3), pp. 325-336. Date of Electronic Publication: 2024 Feb 27.
Typ publikacji:
Multicenter Study; Clinical Trial, Phase II; Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/pathology
Liver Neoplasms*/pathology
Chemoembolization, Therapeutic*/methods
Humans ; Epirubicin ; Microspheres ; Prospective Studies ; Treatment Outcome ; Doxorubicin ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Transarterial Chemoembolization Plus Tyrosinkinase Inhibitors and PD-1 Inhibitors for Spontaneously Ruptured Hepatocellular Carcinoma.
Autorzy:
Ji J; Department of Interventional Radiology, Northern Jiangsu People's Hospital, 98 West Nantong Road, Yangzhou, 225001, China.
Zhou C; Department of Radiology, Interventional Radiology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Gulou, Nanjing, 210029, China.
Yan LL; Department of Interventional Radiology, Northern Jiangsu People's Hospital, 98 West Nantong Road, Yangzhou, 225001, China.
Ma Y; Department of Interventional Radiology, Northern Jiangsu People's Hospital, 98 West Nantong Road, Yangzhou, 225001, China.
Xu C; Department of Interventional Radiology, Northern Jiangsu People's Hospital, 98 West Nantong Road, Yangzhou, 225001, China.
Wang FA; Department of Interventional Radiology, Northern Jiangsu People's Hospital, 98 West Nantong Road, Yangzhou, 225001, China.
Zhou WZ; Department of Radiology, Interventional Radiology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Gulou, Nanjing, 210029, China.
Lv PH; Department of Interventional Radiology, Northern Jiangsu People's Hospital, 98 West Nantong Road, Yangzhou, 225001, China. .
Pokaż więcej
Źródło:
Cardiovascular and interventional radiology [Cardiovasc Intervent Radiol] 2024 Mar; Vol. 47 (3), pp. 299-309. Date of Electronic Publication: 2024 Jan 30.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/pathology
Liver Neoplasms*/pathology
Chemoembolization, Therapeutic*/adverse effects
Peritoneal Neoplasms*/therapy
Peritoneal Neoplasms*/etiology
Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Cirrhotic hepatocellular carcinoma-based decellularized liver cancer model for local chemoembolization evaluation.
Autorzy:
Wang M; Department of Biomedical Engineering, Shenzhen Key Laboratory of Smart Healthcare Engineering, Guangdong Provincial Key Laboratory of Advanced Biomaterials, Southern University of Science and Technology, Shenzhen, Guangdong 518055, China.
Gao Y; Department of Biomedical Engineering, Shenzhen Key Laboratory of Smart Healthcare Engineering, Guangdong Provincial Key Laboratory of Advanced Biomaterials, Southern University of Science and Technology, Shenzhen, Guangdong 518055, China; Department of Chemistry and Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Gibbet Hill Road, Coventry CV4 7AL, UK.
Liu X; Department of Biomedical Engineering, Shenzhen Key Laboratory of Smart Healthcare Engineering, Guangdong Provincial Key Laboratory of Advanced Biomaterials, Southern University of Science and Technology, Shenzhen, Guangdong 518055, China.
Li Z; Department of Biomedical Engineering, Shenzhen Key Laboratory of Smart Healthcare Engineering, Guangdong Provincial Key Laboratory of Advanced Biomaterials, Southern University of Science and Technology, Shenzhen, Guangdong 518055, China.
Xiao J; Department of Biomedical Engineering, Shenzhen Key Laboratory of Smart Healthcare Engineering, Guangdong Provincial Key Laboratory of Advanced Biomaterials, Southern University of Science and Technology, Shenzhen, Guangdong 518055, China.
Gao X; Department of Biomedical Engineering, Shenzhen Key Laboratory of Smart Healthcare Engineering, Guangdong Provincial Key Laboratory of Advanced Biomaterials, Southern University of Science and Technology, Shenzhen, Guangdong 518055, China.
Gibson MI; Department of Chemistry and Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Gibbet Hill Road, Coventry CV4 7AL, UK; Department of Chemistry, University of Manchester, Oxford Road, Manchester M13 9PL, UK; Manchester Institute of Biotechnology, University of Manchester, 131 Princess St, Manchester M1 7DN, UK.
Guo Q; Department of Biomedical Engineering, Shenzhen Key Laboratory of Smart Healthcare Engineering, Guangdong Provincial Key Laboratory of Advanced Biomaterials, Southern University of Science and Technology, Shenzhen, Guangdong 518055, China. Electronic address: .
Pokaż więcej
Źródło:
Acta biomaterialia [Acta Biomater] 2024 Mar 01; Vol. 176, pp. 144-155. Date of Electronic Publication: 2024 Jan 18.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/therapy
Carcinoma, Hepatocellular*/drug therapy
Liver Neoplasms*/drug therapy
Chemoembolization, Therapeutic*
Antineoplastic Agents*/therapeutic use
Humans ; Liver Cirrhosis ; Tumor Microenvironment
Czasopismo naukowe
Tytuł:
Development of an immunosuppressed orthotopic hepatocellular carcinoma rat model for the evaluation of chemo- and radioembolization therapies.
Autorzy:
Charles L; Faculty of Pharmaceutical Sciences, 2405 Wesbrook Mall, Vancouver, BC, V6T 1Z3, CANADA.
Sekar S; Faculty of Pharmaceutical Sciences, 2405 Wesbrook Mall, Vancouver, BC, V6T 1Z3, CANADA.
Osooly M; Faculty of Pharmaceutical Sciences, 2405 Wesbrook Mall, Vancouver, BC, V6T 1Z3, CANADA.
Javed S; Faculty of Pharmaceutical Sciences, 2405 Wesbrook Mall, Vancouver, BC, V6T 1Z3, CANADA.
Williams KC; Faculty of Pharmaceutical Sciences, 2405 Wesbrook Mall, Vancouver, BC, V6T 1Z3, CANADA.
Welch I; Centre of Comparative Medicine, University of British Columbia, 4145 Wesbrook Mall, Vancouver, BC V6T 1W5, CANADA.
Barta I; Centre of Comparative Medicine, University of British Columbia, 4145 Wesbrook Mall, Vancouver, BC V6T 1W5, CANADA.
Saatchi K; Faculty of Pharmaceutical Sciences, 2405 Wesbrook Mall, Vancouver, BC, V6T 1Z3, CANADA. Electronic address: .
Häfeli UO; Faculty of Pharmaceutical Sciences, 2405 Wesbrook Mall, Vancouver, BC, V6T 1Z3, CANADA; Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, DK-2100 Copenhagen, Denmark. Electronic address: .
Pokaż więcej
Źródło:
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V [Eur J Pharm Biopharm] 2024 Mar; Vol. 196, pp. 114180. Date of Electronic Publication: 2024 Jan 16.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/drug therapy
Liver Neoplasms*/therapy
Chemoembolization, Therapeutic*/methods
Rats ; Male ; Female ; Animals ; Rats, Sprague-Dawley ; Models, Animal
Czasopismo naukowe
Tytuł:
5-FU promotes HBV replication through oxidative stress-induced autophagy dysfunction.
Autorzy:
Yang J; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China.
Zheng L; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China.
Yang Z; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China.
Wei Z; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China.
Shao J; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China.
Zhang Y; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China.
Yao J; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China.
Li M; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China.
Wang X; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China. Electronic address: .
Zheng M; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China. Electronic address: .
Pokaż więcej
Źródło:
Free radical biology & medicine [Free Radic Biol Med] 2024 Mar; Vol. 213, pp. 233-247. Date of Electronic Publication: 2024 Jan 10.
Typ publikacji:
Meta-Analysis; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Hepatocellular*/drug therapy
Carcinoma, Hepatocellular*/genetics
Liver Neoplasms*/drug therapy
Liver Neoplasms*/genetics
Chemoembolization, Therapeutic*/methods
Mice ; Animals ; Humans ; Hepatitis B virus/genetics ; Reactive Oxygen Species/pharmacology ; Autophagy ; Oxidative Stress ; Fluorouracil/pharmacology ; Virus Replication
Czasopismo naukowe
Tytuł:
Transarterial Chemoembolization Using Idarubicin Versus Doxorubicin Chemoemulsion in Patients with Hepatocellular Carcinoma (IDADOX): Protocol for a Randomized, Non-inferiority, Double-Blind Trial.
Autorzy:
Choi JW; Department of Radiology, Seoul National University Hospital, #101 Daehak-ro, Jongno-gu, Seoul, 03080, Korea. .; Department of Radiology, Seoul National University College of Medicine, Seoul, Korea. .
Kim HC; Department of Radiology, Seoul National University Hospital, #101 Daehak-ro, Jongno-gu, Seoul, 03080, Korea.; Department of Radiology, Seoul National University College of Medicine, Seoul, Korea.
Han J; Medical Research Collaborating Center, Seoul National University Hospital, Seoul, Korea.
Jang MJ; Medical Research Collaborating Center, Seoul National University Hospital, Seoul, Korea.
Chung JW; Department of Radiology, Seoul National University Hospital, #101 Daehak-ro, Jongno-gu, Seoul, 03080, Korea.; Department of Radiology, Seoul National University College of Medicine, Seoul, Korea.
Pokaż więcej
Źródło:
Cardiovascular and interventional radiology [Cardiovasc Intervent Radiol] 2024 Mar; Vol. 47 (3), pp. 372-378. Date of Electronic Publication: 2023 Dec 26.
Typ publikacji:
Clinical Trial Protocol; Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/therapy
Carcinoma, Hepatocellular*/drug therapy
Liver Neoplasms*/therapy
Liver Neoplasms*/drug therapy
Chemoembolization, Therapeutic*/methods
Humans ; Idarubicin/therapeutic use ; Prospective Studies ; Treatment Outcome ; Doxorubicin/therapeutic use ; Randomized Controlled Trials as Topic ; Clinical Trials, Phase II as Topic
Czasopismo naukowe
Tytuł:
Application of temperature-sensitive liquid embolic agent loaded with oxaliplatin in the TACE procedure for rabbit VX2 gastric cancer.
Autorzy:
Li Y; Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, People's Republic of China.
Ge X; Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, People's Republic of China.
Li Z; Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, People's Republic of China.
Zhou Z; Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, People's Republic of China.
Wu K; Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, People's Republic of China.
Li Y; Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, People's Republic of China.
Ji T; Department of Peripheral Vascular, Zhoukou Chinese Medicine Hospital, Zhoukou, 466000, People's Republic of China.
Wang C; Department of Peripheral Vascular, Zhoukou Chinese Medicine Hospital, Zhoukou, 466000, People's Republic of China.
Guo K; Department of Oncology, Yellow River Sanmenxia Hospital, Sanmenxia, 472000, People's Republic of China.
Ren J; Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, People's Republic of China.
Han X; Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, People's Republic of China. .; Interventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, 450052, People's Republic of China. .; Interventional Institute of Zhengzhou University, Zhengzhou, 450052, People's Republic of China. .
Ren K; Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, People's Republic of China. .; Engineering Technology Research Center for Minimally Invasive, Interventional Tumors of Henan Province, Zhengzhou, 450052, Henan, China. .
Pokaż więcej
Źródło:
Drug delivery and translational research [Drug Deliv Transl Res] 2024 Mar; Vol. 14 (3), pp. 705-717. Date of Electronic Publication: 2023 Sep 05.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*
Liver Neoplasms*/therapy
Chemoembolization, Therapeutic*/methods
Stomach Neoplasms*/drug therapy
Animals ; Rabbits ; Oxaliplatin ; Temperature ; Vascular Endothelial Growth Factor A
Czasopismo naukowe
Tytuł:
Successful hepatic arterial chemoembolization for metastatic melanoma resistant to immune checkpoint inhibitors in an extremely aged patient.
Autorzy:
Kurokami Y; Department of Dermatology, Osaka University Graduate School of Medicine, Osaka, Japan.
Yamashita C; Department of Dermatology, Osaka University Graduate School of Medicine, Osaka, Japan.
Yokoi K; Department of Dermatology, Osaka University Graduate School of Medicine, Osaka, Japan.
Tonomura K; Department of Dermatology, Osaka University Graduate School of Medicine, Osaka, Japan.
Kiyohara E; Department of Dermatology, Osaka University Graduate School of Medicine, Osaka, Japan.
Ishitsuka Y; Department of Dermatology, Osaka University Graduate School of Medicine, Osaka, Japan.
Ono Y; Department of Diagnostic and Interventional radiology, Osaka University Graduate School of Medicine, Osaka, Japan.
Higashihara H; Department of High Precision Image-guided Percutaneous Intervention, Osaka University Graduate School of Medicine, Osaka, Japan.
Fujimoto M; Department of Dermatology, Osaka University Graduate School of Medicine, Osaka, Japan.
Tanemura A; Department of Dermatology, Osaka University Graduate School of Medicine, Osaka, Japan.
Pokaż więcej
Źródło:
The Journal of dermatology [J Dermatol] 2024 Mar; Vol. 51 (3), pp. e66-e67. Date of Electronic Publication: 2023 Jul 12.
Typ publikacji:
Letter
MeSH Terms:
Melanoma*/drug therapy
Melanoma*/secondary
Liver Neoplasms*/drug therapy
Liver Neoplasms*/secondary
Chemoembolization, Therapeutic*
Humans ; Aged ; Immune Checkpoint Inhibitors/therapeutic use
Opinia redakcyjna
Tytuł:
Prognostic nomogram model for selecting between transarterial chemoembolization plus lenvatinib, with and without PD-1 inhibitor in unresectable hepatocellular carcinoma.
Autorzy:
Sheng Y; Department of Interventional Radiology, Third Affiliated Hospital of Soochow University & Changzhou First People's Hospital, Juqian street NO.185, Tianning district, Changzhou, Jiangsu, 213003, China.
Wang Q; Department of Radiology, Third Affiliated Hospital of Soochow University, Changzhou & Changzhou First People's Hospital, Juqian street NO.185, Tianning district, Changzhou, Jiangsu, 213003, China.
Liu H; Department of Radiology, Third Affiliated Hospital of Soochow University, Changzhou & Changzhou First People's Hospital, Juqian street NO.185, Tianning district, Changzhou, Jiangsu, 213003, China.
Wang Q; Department of Interventional Radiology, Third Affiliated Hospital of Soochow University & Changzhou First People's Hospital, Juqian street NO.185, Tianning district, Changzhou, Jiangsu, 213003, China.
Chen W; Department of Interventional Radiology, Third Affiliated Hospital of Soochow University & Changzhou First People's Hospital, Juqian street NO.185, Tianning district, Changzhou, Jiangsu, 213003, China.
Xing W; Department of Radiology, Third Affiliated Hospital of Soochow University, Changzhou & Changzhou First People's Hospital, Juqian street NO.185, Tianning district, Changzhou, Jiangsu, 213003, China.
Pokaż więcej
Źródło:
The British journal of radiology [Br J Radiol] 2024 Feb 28; Vol. 97 (1155), pp. 668-679.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/therapy
Liver Neoplasms*/therapy
Chemoembolization, Therapeutic*
Phenylurea Compounds*
Quinolines*
Humans ; Prognosis ; Nomograms ; Immune Checkpoint Inhibitors ; Retrospective Studies
Czasopismo naukowe
Tytuł:
[The clinical value of heat shock protein 90α in predicting the prognosis of interventional therapy for hepatocellular carcinoma].
Autorzy:
Sun W; Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Li X; Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Pokaż więcej
Źródło:
Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2024 Feb 23; Vol. 46 (2), pp. 118-126.
Typ publikacji:
English Abstract; Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/pathology
Liver Neoplasms*/pathology
Chemoembolization, Therapeutic*/adverse effects
Humans ; Retrospective Studies ; Prognosis ; Treatment Outcome ; Neoplasm Staging
Czasopismo naukowe
Tytuł:
Utility and predictive value of the CRAFITY score in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus tyrosine kinase inhibitors and PD-1 inhibitor.
Autorzy:
Zhang L; Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Road, 430022, Wuhan, China.; Hubei Province Key Laboratory of Molecular Imaging, 430022, Wuhan, China.
Sun T; Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Road, 430022, Wuhan, China.; Hubei Province Key Laboratory of Molecular Imaging, 430022, Wuhan, China.
Sun B; Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Road, 430022, Wuhan, China.; Hubei Province Key Laboratory of Molecular Imaging, 430022, Wuhan, China.
Zhang K; Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Road, 430022, Wuhan, China.; Hubei Province Key Laboratory of Molecular Imaging, 430022, Wuhan, China.
Zheng Y; Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Road, 430022, Wuhan, China.; Hubei Province Key Laboratory of Molecular Imaging, 430022, Wuhan, China.
Li N; Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Road, 430022, Wuhan, China.; Hubei Province Key Laboratory of Molecular Imaging, 430022, Wuhan, China.
Chen L; Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Road, 430022, Wuhan, China.; Hubei Province Key Laboratory of Molecular Imaging, 430022, Wuhan, China.
Zheng C; Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Road, 430022, Wuhan, China. .; Hubei Province Key Laboratory of Molecular Imaging, 430022, Wuhan, China. .
Liang B; Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Road, 430022, Wuhan, China. .; Hubei Province Key Laboratory of Molecular Imaging, 430022, Wuhan, China. .
Shi H; Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Road, 430022, Wuhan, China. .; Hubei Province Key Laboratory of Molecular Imaging, 430022, Wuhan, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2024 Feb 16; Vol. 24 (1), pp. 223. Date of Electronic Publication: 2024 Feb 16.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/drug therapy
Liver Neoplasms*/therapy
Chemoembolization, Therapeutic*
Humans ; Immune Checkpoint Inhibitors ; Tyrosine Kinase Inhibitors ; Retrospective Studies ; alpha-Fetoproteins
Czasopismo naukowe
Tytuł:
Efficacy of radiotherapy in combined treatment of hepatocellular carcinoma patients with portal vein tumor thrombus: a real-world study.
Autorzy:
Xiao Y; Department of Pathology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.
Li K; Hepatopancereatobiliary Center, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.
Zhao Y; Department of Radiation Oncology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, 168 Litang Road, Changping District, Beijing, China.
Yang S; Hepatopancereatobiliary Center, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.
Yan J; Hepatopancereatobiliary Center, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.
Xiang C; Hepatopancereatobiliary Center, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.
Zeng J; Hepatopancereatobiliary Center, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.
Lu Q; Hepatopancereatobiliary Center, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.
Zhang C; Imaging department, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.
Li G; Department of Radiation Oncology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, 168 Litang Road, Changping District, Beijing, China.
Li G; Department of Radiation Oncology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, 168 Litang Road, Changping District, Beijing, China. .
Dong J; Hepatopancereatobiliary Center, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.; Research Unit of Precision Hepatobiliary Surgery Paradigm, Chinese Academy of Medical Sciences, Beijing, China.
Pokaż więcej
Źródło:
BMC surgery [BMC Surg] 2024 Feb 14; Vol. 24 (1), pp. 54. Date of Electronic Publication: 2024 Feb 14.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/surgery
Liver Neoplasms*/surgery
Thrombosis*/pathology
Chemoembolization, Therapeutic*
Humans ; Portal Vein/pathology ; Retrospective Studies ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Peripheral blood lymphocyte subsets predict the efficacy of TACE with or without PD-1 inhibitors in patients with hepatocellular carcinoma: a prospective clinical study.
Autorzy:
Wang H; Department of Interventional Therapy, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.; Guangdong Provincial Key laboratory of Chinese Medicine for Prevention and Treatment of Refractory Chronic Diseases, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Huang H; Department of Laboratory Medicine, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.
Liu T; Department of Laboratory Medicine, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.; State Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Chen Y; Department of Laboratory Medicine, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Li J; Department of Interventional Therapy, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
He M; Department of Laboratory Medicine, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.
Peng J; Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Liang E; Department of Laboratory Medicine, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.
Li J; Department of Interventional Oncology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
Liu W; Department of Interventional Therapy, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Pokaż więcej
Źródło:
Frontiers in immunology [Front Immunol] 2024 Feb 09; Vol. 15, pp. 1325330. Date of Electronic Publication: 2024 Feb 09 (Print Publication: 2024).
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/pathology
Liver Neoplasms*/pathology
Chemoembolization, Therapeutic*
Humans ; Immune Checkpoint Inhibitors/therapeutic use ; CD28 Antigens ; Prospective Studies ; Programmed Cell Death 1 Receptor ; Lymphocyte Subsets/pathology
Czasopismo naukowe
Tytuł:
Impact of preoperative transcatheter arterial chemoembolization (TACE) on postoperative long-term survival in patients with nonsmall hepatocellular carcinoma: a propensity score matching analysis.
Autorzy:
Hu R; The Second Affiliated Hospital of Chongqing Medical University, 74# Linjiang Road, Yuzhong District, Chongqing, 400000, China.
Xu J; The Second Affiliated Hospital of Chongqing Medical University, 74# Linjiang Road, Yuzhong District, Chongqing, 400000, China.
Wang H; The Second Affiliated Hospital of Chongqing Medical University, 74# Linjiang Road, Yuzhong District, Chongqing, 400000, China.
Wang J; The Second Affiliated Hospital of Chongqing Medical University, 74# Linjiang Road, Yuzhong District, Chongqing, 400000, China.
Lei K; The Second Affiliated Hospital of Chongqing Medical University, 74# Linjiang Road, Yuzhong District, Chongqing, 400000, China.
Zhao X; The Second Affiliated Hospital of Chongqing Medical University, 74# Linjiang Road, Yuzhong District, Chongqing, 400000, China.
Zhang H; The Second Affiliated Hospital of Chongqing Medical University, 74# Linjiang Road, Yuzhong District, Chongqing, 400000, China.
You K; The Second Affiliated Hospital of Chongqing Medical University, 74# Linjiang Road, Yuzhong District, Chongqing, 400000, China.
Liu Z; The Second Affiliated Hospital of Chongqing Medical University, 74# Linjiang Road, Yuzhong District, Chongqing, 400000, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2024 Feb 09; Vol. 24 (1), pp. 190. Date of Electronic Publication: 2024 Feb 09.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/pathology
Liver Neoplasms*/pathology
Chemoembolization, Therapeutic*
Humans ; Propensity Score ; Retrospective Studies ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Development of a predictive nomogram for postembolization syndrome after transcatheter arterial chemoembolization of hepatocellular carcinoma.
Autorzy:
Bai J; Minimally Invasive Intervention Department, The Third Affiliated Hospital of Kunming Medical University, Kunming, 650118, China.
Huang M; Minimally Invasive Intervention Department, The Third Affiliated Hospital of Kunming Medical University, Kunming, 650118, China.
Zhou J; Minimally Invasive Intervention Department, The Third Affiliated Hospital of Kunming Medical University, Kunming, 650118, China.
Song B; Minimally Invasive Intervention Department, The Third Affiliated Hospital of Kunming Medical University, Kunming, 650118, China.
Hua J; Minimally Invasive Intervention Department, The Third Affiliated Hospital of Kunming Medical University, Kunming, 650118, China.
Ding R; Minimally Invasive Intervention Department, The Third Affiliated Hospital of Kunming Medical University, Kunming, 650118, China. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Feb 08; Vol. 14 (1), pp. 3303. Date of Electronic Publication: 2024 Feb 08.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/therapy
Carcinoma, Hepatocellular*/pathology
Chemoembolization, Therapeutic*/adverse effects
Liver Neoplasms*/therapy
Liver Neoplasms*/pathology
Humans ; Nomograms ; Retrospective Studies ; Syndrome
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies